Table 1.
Drugs targeting ferroptosis in liver diseases.
| Drugs | Ferroptosis | Target | Mechanism |
|---|---|---|---|
| Erastin [43,44] | Inducer | System Xc− | Inhibits system Xc−, resulting in GSH depletion |
| Sulfasalazine [47,48,49] | Inducer | System Xc− | Inhibits system Xc−, resulting in GSH depletion |
| Sorafenib [50,51,52] | Inducer | System Xc− | Inhibits system Xc−, resulting in GSH depletion |
| Statins [55] | Inducer | HMG-CoA reductase | Depletes CoQ10, resulting in lipid peroxidation |
| Artesunate [56,57] | Inducer | Ferritinophagy | Activates ferritinophagy |
| Magnesium isoglycyrrhizinate [59] | Inducer | HO-1 | Up-regulates HO-1 |
| Fer-1 [5,11,39,60] | Inhibitor | PUFAs | Inhibits lipid peroxidation |
| Vitamin E [61,62,63] | Inhibitor | PUFAs | Inhibits lipid peroxidation |
| Dimethyl fumarate [64] | Inhibitor | Nrf2 | Activates Nrf2, leading to reducing lipid peroxidation |
| Rosiglitazone [19,65] | Inhibitor | ACSL4 | Inhibits ACSL4, leading to reducing lipid peroxidation |
| Dehydroabietic acid [69] | Inhibitor | Nrf2 | Activates Nrf2, leading to reducing lipid peroxidation |
| Ginkgolide B [70] | Inhibitor | Nrf2 | Activates Nrf2, leading to reducing lipid peroxidation |
Abbreviations: ACSL4, acyl-CoA synthetase long-chain family member 4; CoQ10, coenzyme Q10; GSH, glutathione; HO-1, heme oxygenase-1; Nrf2, nuclear factor erythroid 2-related factor 2; PUFAs, polyunsaturated fatty acids.